AzTrials
AzTrials

RecruitmentOSPREYNCT07290335

Optimizing Strategies to Maximize Patient Recruitment Yield

A study testing Positively-valenced message, Payment-inclusive message and Positively-valenced, payment-inclusive message in people with Recruitment, run by Emory University at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This platform trial aims to evaluate the effectiveness of different messaging strategies within a MyChart messaging program for research recruitment. MyChart is a patient portal system within the Electronic Medical Record (EMR), and messages can be sent directly to patients about research opportunities. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Recruitment
What is being tested?
Positively-valenced message, Payment-inclusive message and Positively-valenced, payment-inclusive message
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100,000 participants
Where
1 siteUnited States
Study dates
19 Feb 2026to Apr 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • All patients receiving messages via MyChart will be included
  • Potential eligibility for a study using MyChart requirement based on the planned query/criteria for that study.

Who cannot join

  • Minor
  • Excluded from primary study that is recruiting participants.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Neal Dickert, MD, PhD contact

(404) 712-6834

njr@emory.edu

United States1 site, 1 recruiting
  • Emory Healthcare System

    Atlanta, Georgia, 30322

    Recruiting

Other trials in United States

About this study

This platform trial aims to evaluate the effectiveness of different messaging strategies within a MyChart messaging program for research recruitment. MyChart is a patient portal system within the Electronic Medical Record (EMR), and messages can be sent directly to patients about research opportunities.

Read the detailed description

Recruitment of participants presents a significant and persistent bottle neck in the research process. Failure to reach participant enrollment targets may delay or halt study progression, wasting limited resources. Insufficient rates of participant accrual are the leading cause for termination among clinical trials with results posted on ClinicalTrials.gov. Additionally, studies must enroll representative samples to ensure generalizability and comply with NIH guidelines. Investigators often cite recruitment difficulties - including lack of interest, difficulty reaching specific populations, and limited resources - to explain failure to reach enrollment goals. However, these recruitment difficulties may not actually be due to a lack of willingness to participate among eligible patients. A national survey conducted by Harris Interactive in 2001 found that 85% of patients were either unaware or unsure that participation in a clinical trial was an option at the time of diagnosis. 75% of these patients said they would have been willing to enroll had they known it was possible. Innovation in recruitment is sorely needed to make recruitment more efficient and more representative.

In recent years, researchers have begun to leverage patient portals and electronic health records (EHRs) for recruitment. This method allows for engagement of broad populations within a health system in a cost-effective way. Emerging evidence of EHR recruitment shows promise. The researchers of this study have examined the use of EHR recruitment to identify and contact eligible patients via MyChart direct-to-patient messaging across a range studies within Emory Healthcare. Having completed a pilot program within the Emory system, this service is now available to all Emory investigators for whom MyChart recruitment is appropriate.

While the feasibility of MyChart messaging has been documented, little is known about best practices for how recruitment messages should be designed. There are, however, good reasons to believe that how messages are designed and framed may impact potential participants' responses to them.

This project is a platform trial that will allow for serial testing of various aspects of portal-based messaging. Consistent with platform trial design, the researchers will use a common set of outcome measures across various studies, and the portal-based messaging strategy allows for easy randomization (generally at the patient level) of patients to specific messaging approaches.

In the context of broader use of MyChart messaging, the researchers have designed this study to examine the impact of message design on patients' responses. Specifically, this study will examine the impact of including positively-valenced language that describes the value of the study and the impact of inclusion of information regarding any payments that participants will receive in the study. Both of these factors are ones that are grounded in behavioral economics and may be meaningful to potential participants.

The first proposed trial will involve randomly assigning patients who are identified as potentially eligible for studies using the MyChart recruitment mechanism to receive a recruitment message using 1 of 4 templates: 1) the current standard template; 2) a template with inclusion of positively-valenced language describing the study's value; 3) a template containing information about payment to participants; and 4) a template with both positively-valenced language and payment information. For all studies using the MyChart mechanism, all 4 messages will be created, and assignment will be done based on the last two digits of the patient's medical record number (MRN).

The primary endpoint is the rate at which individuals respond that they are interested in participating in the study to which they are invited. Additionally, this study will examine the non-response rate and the rate of individuals responding that they are not interested in the study. It will also track the rate at which individuals exposed to a MyChart recruitment message change their permission settings for contact about research opportunities. Study teams whose study invitations are used in this trial will be contacted about the rate of enrollment among patients who responded as "interested" to the message so that the researchers can estimate enrollment rate within each intervention group. Finally, select patients will participate in short interviews to understand their impressions of the message they were sent and their attitudes towards research more generally.

Conditions
Recruitment
Being tested
Baseline (control) message, Positively-valenced message, Payment-inclusive message, Positively-valenced, payment-inclusive message
Keywords
Research recruitment, Patient portal-based communication

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Baseline (control) messageBehavioural

    The MyChart study recruitment program will send a message based on the current template, which is a brief message with a neutral tone.

  • Positively-valenced messageBehavioural

    The MyChart study recruitment program will send a message based on a template that contains positively-valenced language related to the value/importance of the study.

  • Payment-inclusive messageBehavioural

    The MyChart study recruitment program will send a message based on a template that includes more detailed information about participant payment.

  • Positively-valenced, payment-inclusive messageBehavioural

    The MyChart study recruitment program will send a message based on a template that includes both positively-valenced language and detailed information about participant payment.

Study groups in NCT07290335
Study groupRoleWhat they receive
Baseline (control) messageActive comparatorPatients in the Emory Healthcare system, who have not opted out of research contact, receiving MyChart messaging for research recruitment using the current standard template.
Receives: Behavioral: Baseline (control) message
Positively-valenced messageExperimentalPatients in the Emory Healthcare system, who have not opted out of research contact, receiving MyChart messaging for research recruitment using a template with inclusion of positively-valenced language describing the study's value.
Receives: Behavioral: Positively-valenced message
Payment-inclusive messageExperimentalPatients in the Emory Healthcare system, who have not opted out of research contact, receiving MyChart messaging for research recruitment using a template containing information about payment to participants.
Receives: Behavioral: Payment-inclusive message
Positively-valenced, payment-inclusive messageExperimentalPatients in the Emory Healthcare system, who have not opted out of research contact, receiving MyChart messaging for research recruitment using a template with both positively-valenced language and payment information.
Receives: Behavioral: Positively-valenced, payment-inclusive message

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rate of "interested" response to recruitment messages

    The primary endpoint is the rate at which individuals respond that they are interested in participating in the study to which they are invited. The primary outcome is a binary variable of "interested" response.

    Measured: Month 12

Secondary outcomes (6)
  1. Rate of non-response

    This study will examine the rate of non-response to recruitment messages.

    Measured: Month 12

  2. Rate of "not interested" responses

    This study will examine the rate of individuals responding that they are not interested in the study.

    Measured: Month 12

  3. Rate of change in MyChart permissions to contact

    This study will examine the rate at which individuals exposed to a MyChart recruitment message change their permission settings for contact about research opportunities.

    Measured: Month 12

  4. Rate of enrollment among "interested" patients

    Study teams whose study invitations are used in this trial will be contacted about the rate of enrollment among patients who responded as "interested" to the message.

    Measured: Month 12

  5. Patient impressions on recruitment messages

    Some patients will participate in short interviews to understand their impressions of the message they were sent. Qualitative data are collected during the interviews and there is not a standardized questionnaire or scale that will be used.

    Measured: Month 12

  6. Patient impressions on research in general

    Some patients will participate in short interviews to understand their attitudes towards research more generally. Qualitative data are collected during the interviews and there is not a standardized questionnaire or scale that will be used.

    Measured: Month 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Dec 2025
  2. Study start19 Feb 2026
  3. Primary completionApr 2027 (estimated)
  4. Study completionApr 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
100,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07290335
Sponsor's protocol ID
2025P013508
Other IDs
UL1TR002378
Acronym
OSPREY
Status last verified
Feb 2026
First submitted
15 Dec 2025
Last updated
25 Feb 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Deidentified data will be available for sharing. This will include deidentified participant-level demographic characteristics, intervention assignment, and enrollment/non-enrollment status within the parent trial. This will include a de-identified data spreadsheet, readme file, and a data dictionary.

Questions about this trial

What is this clinical trial studying?

A study testing Positively-valenced message, Payment-inclusive message and Positively-valenced, payment-inclusive message in people with Recruitment, run by Emory University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 25 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Neal Dickert, MD, PhD ((404) 712-6834, njr@emory.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rate of "interested" response to recruitment messages (time frame: Month 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Feb 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in